biologics manufacturing
biologics manufacturing
Revolutionary Model Predicts Biologic Processing Variations
🔍 Scientists have developed a mathematical model to predict RTD in continuous manufacturing of biologics. 🔬🔬🧪💯🔬
Merck Revolutionizes Biosafety Testing with Game-Changing Genetic Stability Assay
Merck introduces a game-changing genetic stability assay for biosafety testing, simplifying and reducing time and costs. 🧬💼
Ascend Acquires GMP Facility Boosts Gene Therapy
📢 Ascend Advanced Therapies secures Beacon Therapeutics' GMP facility in Florida, boosting gene therapy expertise and product supply. 🔬🤝👁️
Lonza Partners with Acumen for Alzheimer’s Breakthrough
📰 Lonza teams up with Acumen to make sabirnetug, a groundbreaking Alzheimer's therapy, at their New Hampshire facility. 👥 🧪 Sabirnetug targets toxic amyloid beta oligomers, offering hope in the fight against Alzheimer's. 💡 ⏩ Exciting collaboration to speed up Alzheimer's treatment development. Lonza Acumen AlzheimersTherapy Sabirnetug
Boost mRNA Manufacturing with Digital Optimization
📰 Researchers in Germany developed a digital model to optimize mRNA manufacturing, resulting in increased production and reduced truncation. 💻💉
FDA Releases Game-Changing CAR-T Guidelines: Everything You Need to Know!
📢 The FDA published new guidance for CAR-T cell products, covering change management, risk assessment, flow cytometry, and more. 👩🔬🔬🧪🗂 CAR-T FDA
Robots and AI Revolutionize Cell and Gene Therapy Manufacturing!
🤖🔬 Researchers suggest that robots and AI can address manufacturing challenges in cell and gene therapy. ⬆️🌍 The industry is growing rapidly, requiring skilled personnel and increased production. 🤖🔬 Automation and AI can improve efficiency and reduce costs.
MilliporeSigma’s €300 Million Investment Fuels South Korea’s Bioproduction Boom
📢 MilliporeSigma invests €300 million in South Korea bioproduction site, creating 300 jobs and supporting biotech and pharma industries. 🏭💼🧪🧬
Lonza Acquires Genentech’s $12B Biologics Site
📢 Lonza buys Genentech's CA biologics manufacturing site for $1.2B, boosting production capabilities for next-gen therapies. 🏭
Syngene’s India Biologics Facility Ready by Mid-Year
📢 Syngene International's new biologics manufacturing facility in India to be operational from mid-year. 💉🏭 Tripled capacity, expansion plans underway!
